| Literature DB >> 35924053 |
Yunlai Wang1,2,3, Ye Feng1, Manman Li1, Mo Yang4, Gaoxiang Shi1, Zihua Xuan1, Dengke Yin1, Fan Xu1,2.
Abstract
Chronic kidney disease (CKD) is a common and progressive disease that has become a major public health problem on a global scale. Renal fibrosis is a common feature in the pathogenesis of CKD, which is mainly related to the excessive accumulation and deposition of extracellular matrix caused by various inflammatory factors. No ideal treatment has yet been established. In recent years, based on the traditional Chinese medicine (TCM) theory of CKD and its molecular mechanism, clinical evidence or experimental studies have confirmed that a variety of Chinese materia medica (CMM) and their effective components can delay the progress of CKD. TCM believes that the pathogenesis of CKD is the deficiency in the root and excess in the branch, and the deficiency and excess are always accompanied by the disease. The strategies of TCM in treating CKD are mainly based on invigorating Qi, tonifying the kidneys, promoting blood circulation, removing stasis, eliminating heat and dampness, removing turbidity, and eliminating edema, and these effects are multitargeted and multifunctional. This review attempts to summarize the theories and treatment strategies of TCM in the treatment of CKD and presents the efficacy and mechanisms of several CMMs supported by clinical evidence or experimental studies. In addition, the relationship between the macroscopic of TCM and the microscopic of modern medicine and the problems faced in further research were also discussed.Entities:
Keywords: Chinese materia medica; chronic kidney disease; intervention mechanism; reinforcing deficiency and purging excess; renal fibrosis; traditional Chinese medicine
Year: 2022 PMID: 35924053 PMCID: PMC9340222 DOI: 10.3389/fphar.2022.917975
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1The corresponding relationship between the pathogenesis of the TCM theory and the modern medicine theory. (A) Characteristics of TCM pathogenesis in the process of chronic kidney disease. In the early stage of CKD, although the spleen and kidneys are insufficient, the vital Qi can still resist exogenous pathogens, and the pathogenesis is characterized by pathogenic excess (such as dampness heat and blood stasis). However, as the disease progresses to the middle stage, the vital Qi cannot overcome the pathogenic factors, various pathological products are formed, and its pathogenesis characteristics change into a mixture of deficiency and excess. When the disease progresses to the terminal stage, the vital Qi is exhausted, and the pathogenesis is characterized by a deficiency of vital Qi (leading to the accumulation of liquid and turbid toxin). In different stages of nephropathy, the priority of the deficiency and the excess are different. Deficiency and excess are cause and effect of each other, which leads to the continuous progress of CKD. (B) Cognition and treatment strategy of CKD in the TCM theory. On the left are the modern medical characteristics and the main pathological process of CKD. On the right is the treatment strategy of TCM using CMM, and the representative CMMs corresponding to each pathogenesis are listed.
Characteristics of TCM formulas on CKD.
| Formulas | TCM efficacy | Composition | Model/cell type | Mechanism | Ref. |
|---|---|---|---|---|---|
| Bu-Shen-Huo-Xue formula | Tonifying kidneys, nourishing Qi, and invigorating blood circulation | Astragali Radix, Curcumae Rhizoma, Rhei radix et Rhizoma, Trigonellae Semen, Vaccariae Semen, Smilacis Glabrae Rhizoma, and Coptidis rhizoma | 5/6 Nx rats | ↓TNF-α, CTGF, TGF-β1, NF-κB, and OPN; ↑PPAR-γ |
|
| Fuzheng Huayu recipe | Strengthening the body resistance and removing stasis | Cordyceps, Salviae Miltiorrhizae Radix et Rhizoma, Persicae Semen, Schisandrae Chinensis Fructus, Pini Pollen, and Gynostemma Pentaphyllammak | HgCl2-RIF rats | ↓TGF-β1, p-Smad2, p-Smad3, TβR-I, miR-21, and AKT; ↑E-cadherin and PTEN |
|
| Fangji Huangqi Tang | Nourishing Qi, strengthening the spleen, and promoting diuresis | Astragali Radix, Stephaniae Tetrandrae Radix, Atractylodis Macrocephalae Rhizoma, and Glycyrrhizae Radix et Rhizoma | ADR-NS rats | ↑Podocin |
|
| Huang Qi Huai granules | Improving Qi and nourishing Yin | Poria Robiniophila, Lycii Fructus, and Polygonati Rhizoma | ADR-NS rats | ↑Nephrin; ↓TNF-α, NF-κB p65, IκBα, Bax, and caspase-3 |
|
| Shenyan Xiaobai granule | Invigorating the spleen and kidneys, clearing heat, and removing dampness | Astragali Radix, Smilacis Glabrae Rhizoma, Codonopsis Radix, Dioscoreae Rhizoma, Coicis Semen, Ligustri Lucidi Fructus, Cuscutae Semen, Rehmanniae Radix Praeparata, Lycii Fructus, Imperatae Rhizoma, Leonuri Herba, and Euryales Semen | ADR-NS rats | ↑Nephrin and podocin |
|
| Yishen Huoxue prescription | Improving Qi, activating Blood, and removing stasis and turbidity | Astragali Radix, Angelicae Sinensis Radix, Chuanxiong Rhizoma, Salvia Miltiorrhizae Radix et Rhizoma, Rhei Radix et Rhizoma, and Notoginseng Radix et Rhizoma | UUO rats | ↑miR-126, VEGFA, VEGFR-2, and Notch1 |
|
| You-gui pill | Warming and recuperating kidney-Yang | Rehmanniae Radix Praeparata, Dioscoreae Rhizoma, Corni Fructus, Lycii Fructus, Cuscutae Semen, Cervi Cornus Colla, Eucommiae Cortex, Cinnamomi Cortex, Angelicae Sinensis Radix, and Aconiti Lateralis Radix Praeparata | UUO rats and TGFβ1-stimulated NRK-49F cells | ↓TGF-β1, α-SMA, FN, Col, and p-Smad2/3 |
|
| Yiqi Huoxue formula | Nourishing Qi, invigorating blood circulation, strengthening the spleen, and promoting diuresis | Astragali Radix, Angelicae Sinensis Radix, Chuanxiong Rhizoma, Salvia Miltiorrhizae Radix et Rhizoma, Paeoniae Radix Rubra, Plantaginis Herba, Achyranthis Bidentatae Radix, and Taraxaci Herba | UUO rats | ↓TGF-β, smad2, and CTGF; ↑smad7 |
|
| Shen Shuai II recipe | Strengthening the spleen, tonifying kidney-Yang, activating blood circulation, and removing stasis | Salvia Miltiorrhizae Radix et Rhizoma, Epimedii Folium, Codonopsis Radix, Angelicae Sinensis Radix, Rhei Radix et Rhizoma, Perillae Folium, Persicae Semen, Chuanxiong Rhizoma, and Coptidis Rhizoma | 5/6 Nx and infarcted rats and hypoxic NRK-52E cells | ↓HIF-1α, c-Myc, IL-1β, Bax, Puma, p53, and cytochrome c |
|
| Shenkang | Improving Qi and removing stasis and turbidity | Rhei Radix et Rhizoma, Salvia Miltiorrhizae Radix et Rhizoma, Carthami Flos, and Astragali Radix | UUO mice, adenine-CRF rats, TGF-β1-stimulated NRK-49F cells, and TAC-NS rats | ↓Prdx5, JAK2/STAT3, SOCS1, SOCS3, NF-κB p65, IκBα, COX-2, MCP-1, iNOS, and Keap1; ↑Nrf2, HO-1, catalase, and GCLC |
|
| Nephrokeli | Nourishing kidneys | Ligustri Lucidi Fructus, Testudinis Carapax et Plastrum, Dioscoreae Rhizoma, Typhae Pollen, Ecliptae Herba, Perilla, Atractylodis Rhizoma, Coicis Semen, Rehmanniae Radix, and Hedyotis Diffusa | IgAN rats and S1P-stimulated MC | ↓CTGF, S1PR2, and S1PR3 |
|
| Qilong-Lishui granule | Tonifying Qi, removing stasis, removing dampness, and promoting diuresis | Bupleuri Radix, Astragali Radix, Angelicae Sinensis Radix, Dioscoreae Nipponicae Rhizoma, Polyporus, and Pyrrosiae Folium | PAN-NS rats | ↓BMPRII and Smad1 |
|
| HuangQi decoction | Nourishing Qi and Yin and tonifying the spleen and kidneys | Astragali Radix, Poria, Rehmanniae Radix, Trichosanthis Radix, Ophiopogonis Radix, Schisandrae Chinensis Fructus, and Glycyrrhizae Radix et Rhizoma Praeparatacum Melle | UUO mice and TGF-β1-stimulated HK2 cells | ↓TGF-β1, TβRI, TβRII, Smad4, Smad2/3, Wnt3/4, Frizzled4, and LRP5/6; ↑GSK-3β, Axin, APC, CK1, and E-cadherin |
|
| Danggui Shaoyao San | Invigorating blood circulation and promoting diuresis | Angelicae Sinensis Radix, Paeoniae Radix Alba Rhizoma, Chuanxiong Rhizoma, Atractylodis Macrocephalae Rhizoma, Alismatis Rhizoma, and Poria | ADR-NS rats and Ang II-stimulated MPC-5 cells | ↑Nephrin; ↓AT1R, TRPC6, and caspase-3 |
|
| Chailing decoction | Smoothing liver, strengthening the spleen, promoting diuresis, and removing turbidity | Bupleuri Radix, Scutellariae Radix, Pinelliae Rhizoma, Ginseng Radix et Rhizoma, Glycyrrhizae Radix et Rhizoma, Zingiberis Rhizoma Recens, Jujubae Fructus, Polyporus, Cinnamomi Ramulus, Atractylodis Macrocephalae Rhizoma, Poria, and Alismatis Rhizoma | CsA-NS rats | ↓α-SMA, TGF-β1, and Col III |
|
| Jianpi qinghua recipe | Invigorating the spleen, improving Qi, clearing heat, and removing dampness | Codonopsis Radix, Astragali Radix, Tsaoko Fructus Semen, Atractylodis Rhizoma, Coptidis Rhizoma, and Prepared Rhei Radix et Rhizoma | ADR-NS rats | ↓α-SMA, Col III, FN, Col IV, IL6, and CD4+/CD8+ |
|
| Shenhua tablet | Tonifying Qi, nourishing Yin, activating Blood, and removing stasis | Astragali Radix, Ligustri Lucidi Fructus, Atractylodis Macrocephalae Rhizoma, Paeoniae Radix Alba Rhizoma, Sparganii Rhizoma, Curcumae Rhizoma, and Lonicerae Japonicae Flos | Anti-Thy-1 nephritis rats, IRI rats, and 5/6 Nx rats | ↓p-Erk1/2, cyclin D1, TLR2, TLR4, MyD88, TNF-α, and IL-6; ↑p21 |
|
| Jian-Pi-Yi-Shen formula | Fortifying the spleen, tonifying the kidneys, activating Blood, and removing stasis | Astragali Radix, Atractylodis Macrocephalae Rhizoma, Dioscoreae Rhizoma, Cistanches Herba, Amomi Fructus Rotundus, Salviae Miltiorrhizae Radix et Rhizoma, Rhei Radix et Rhizoma, and Glycyrrhizae Radix et Rhizoma Praeparatacum Melle | 5/6 Nx rats | ↑Bcl-2, HO-1, and Nrf2; ↓TGF-β, Col I, Col II, Col III, Bax, caspase 3, caspase 9, TNF-α, IL-1β, IκBα, NF-κB p65, MCP-1, CXCL1, COX-2, iNOS, and Keap1 |
|
| Kangxianling | Strengthening Qi and removing stasis | Salvia Miltiorrhizae Radix et Rhizoma, prepared Rhei Radix et Rhizoma, Achyranthis Bidentatae Radix, Persicae Semen, and Angelicae Sinensis Radix | 5/6 Nx rats and Ang II-stimulated HBZY-1 cells | ↓JNK, TGF-β, Col-I, and FN |
|
FIGURE 2Summary of the related mechanism of treating CKD with CMM. TGF-β/Smad and Wnt/β-catenin signaling pathways are two antifibrotic mechanisms that have been confirmed by a variety of TCM studies. Among them, Smad3 is pathogenic in renal fibrosis but Smad7 plays a protective role by negatively regulating the phosphorylation of Smad2/3 and NF-κB-driven inflammatory response. For the dual functions of Smad4, the therapeutic effect of CMM is to inhibit Smad3-dependent renal fibrosis. Besides, the sustained excessive reaction of abnormal activation of the PI3K/Akt/mTOR signaling pathway can lead to an increase in Col I and FN and ultimately lead to renal fibrosis. In the occurrence of glomerular hyperperfusion, hyperfiltration, and hyperglycemia, it causes oxidative stress and AGE activation, followed by a series of inflammatory reactions. In addition to inhibiting the activation of AGE, the antiinflammatory effect of CMM is also manifested in the inhibition of ROS-ERK1/2 and NF-κB-mediated NLRP3 inflammasomes.
Recent trials studying the use of TCM in CKD.
| TCM intervention | Disease |
| Trial period (mo) | Primary outcome | Outcome | Ref. |
|---|---|---|---|---|---|---|
| Shenqi particle vs. prednisone/cyclophosphamide | Idiopathic membranous nephropathy | 190 | 12 | CR + PR | 46/63 (73.0%) vs. 54/69 (78.3%); |
|
| Bupi Yishen formula vs. losartan | Nondiabetic CKD stage 4 | 567 | 12 | eGFR slope | −2.3 vs. −4.5 ml/min/1.73 m2/year ( |
|
| Tangshen formula vs. placebo | Type 2 diabetic kidney disease | 180 | 6 | UAER + 24 h UP | UAER: −19.5 vs. −7.0 μg/min ( |
|
| TCMsa vs. benazepril vs. TCMs/benazepril combination | CKD stage 3 | 578 | 6 | Mean eGFR | 48.5 ± 15.9 vs. 43.0 ± 12.4 vs. 48.3 ± 17.5 ml/min ( |
|
| Niaoduqing particles vs. placebo | CKD stage 3b-4 | 300 | 6 | Changes in Scr and eGFR between pre treatment and posttreatment | Scr: 1.1 vs. 11.7 μmol/L ( |
|
| Zicuiyin decoction vs. Huangkui capsule | Diabetic kidney disease | 88 | 2 | Changes in eGFR between pre treatment and posttreatment | 2.6 ± 18.5 vs. −7.1 ± 24.7 ml/min/1.73 m2 ( |
|
| Huangkui capsule vs. losartan | IgA nephropathy | 1470 | 12 | Changes in 24 h UP between pre treatment and posttreatment | −230 vs. −253 mg ( |
|
| Chinese herbal formula granules vs. placebo | CKD stage 3 | 343 | 6 | 24 h UP + Scr + eGFR | 24 h UP: 1.0 ± 1.1 vs. 1.0 ± 1.3 g/d ( |
|
| TCMsa vs. losartan | CKD stage 1–2 | 396 | 6 | 24 h UP | 801.6 ± 911.7 vs. 1080.6 ± 925.8 mg/L ( |
|
| Huangkui capsule vs. losartan vs. Huangkui capsule/losartan combination | Primary glomerular disease | 417 | 6 | Changes in 24 h UP between pre treatment and posttreatment | −508 vs. −376 mg/d ( |
|
| TCMsa vs. losartan | CKD stage 1–2 | 81 | 6 | 24 h UP | 0.4 ± 0.6 vs. 0.2 ± 0.9 g ( |
|
| Qidan Dihuang grain/angiotensin receptor blocker combination vs. angiotensin receptor blocker | Diabetic kidney disease | 102 | 3 | 24 h albuminuria | 41.4 vs. 47.7 mg ( |
|
| Shenhua tablet vs. fosinopril | IgA nephropathy | 131 | 3 | 24 h UP + TCM syndrome score | 24 h UP: 1.05 ± 1.07 vs. 1.13 ± 1.18 g ( |
|